Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir plus Dasabuvir +/- Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders

SONSUZ A., Bozcan S., HATEMİ A. İ., ÖZDEMİR S., Canbakan B., Yildirim S., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.5, pp.414-420, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 33 Issue: 5
  • Publication Date: 2022
  • Doi Number: 10.5152/tjg.2022.20844
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.414-420
  • Keywords: Chronic viral hepatitis, direct-acting antivirals, hemophilia, inherited coagulation disorders, von Willebrand disease, PROTEASE INHIBITOR THERAPY, HEMOPHILIA PATIENTS, HIV, INTERFERON, MORTALITY, LEDIPASVIR/SOFOSBUVIR, INFECTION, SURVIVAL, COHORT, DEATH
  • Istanbul University Affiliated: No

Abstract

Background: Hepatitis C is one of the leading causes of death in patients with inherited bleeding disorders. Currently, direct-acting antiviral drugs used for the treatment of hepatitis C have become an effective and a reliable option for people with inherited bleeding disorders. The aim of this study is to report the efficacy and safety of ombitasvir + paritaprevir/ritonavir and dasabuvir combination in the treatment of hepatitis C in patients with inherited bleeding disorders.